Monopar TherapeuticsMNPR
13F holders, Q1 2025 (March 31)At the end of Q1 2025, 35 institutions reported holding Monopar Therapeutics Inc. (MNPR) in their 13F filings, up 17 from Q4 2024. 18 opened new positions and 1 sold out. The largest holders were Janus Henderson Group PLC ($45.6M), Adage Capital Partners Gp, L.L.C. ($21.8M) and Ra Capital Management, L.P. ($18.6M). 2 famous investors held it, including Steve Cohen (0.0% of Point72 Asset Management's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Monopar Therapeutics Inc.
- CUSIP
- 61023L207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 18 | $8.6M |
| Exits | 1 | $2K |
All 13F filers, Q4 2024 → Q1 2025: 343,081 shares bought and 35,345 shares sold, net +307,736 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 35 holders
| Janus Henderson Group PLC | 0.03% | Add +8.4% | 1,134,406 | $45.6M |
| Adage Capital Partners Gp, L.L.C. | 0.04% | No change | 599,195 | $21.8M |
| Ra Capital Management, L.P. | 0.31% | No change | 511,207 | $18.6M |
| Point72 Asset Management | 0.02% | Add +0.2% | 168,160 | $6.1M |
| ADAR1 Capital Management, LLC | 0.73% | Reduce -22.5% | 100,774 | $3.7M |
| Affinity Asset Advisors, LLC | 0.37% | New | 62,000 | $2.3M |
| Millennium Management | 0.00% | New | 60,367 | $2.2M |
| Vanguard Group Inc. | 0.00% | Reduce -2.3% | 55,234 | $2.0M |
| Geode Capital Management, LLC | 0.00% | Add +25.8% | 48,540 | $1.8M |
| Marshall Wace, LLP | 0.00% | New | 25,988 | $946K |
| Goldman Sachs Group Inc. | 0.00% | New | 18,480 | $673K |
| State Street Corp. | 0.00% | New | 15,814 | $576K |
| BlackRock, Inc. | 0.00% | Add +78.5% | 14,464 | $527K |
| Jane Street Group, LLC | 0.00% | New | 10,357 | $377K |
| Northern Trust Corp. | 0.00% | New | 9,161 | $334K |
| OMERS ADMINISTRATION Corp | 0.00% | New | 9,000 | $328K |
| HRT Financial LP | 0.00% | New | 8,228 | $299K |
| UBS Group AG | 0.00% | Add +26.4% | 8,121 | $296K |
| Balyasny Asset Management L.P. | 0.00% | New | 6,141 | $224K |
| Ikarian Capital, LLC | 0.07% | No change | 5,908 | $215K |
| Gerber, LLC | 0.17% | New | 5,601 | $204K |
| Bank of America Corp. | 0.00% | Add +8750.0% | 2,478 | $90K |
| Point72 Asia (Singapore) Pte. Ltd. | 0.02% | New | 1,761 | $64K |
| Morgan Stanley | 0.00% | Reduce -62.5% | 1,424 | $52K |
| AlphaQuest LLC | 0.00% | New | 1,215 | $44K |
| NewEdge Advisors, LLC | 0.00% | No change | 600 | $22K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -56.5% | 303 | $11K |
| Wells Fargo & Company | 0.00% | No change | 250 | $9K |
| Citigroup Inc. | 0.00% | New | 225 | $8K |
| Point72 (DIFC) Ltd | 0.00% | New | 196 | $7K |
| Royal Bank of Canada | 0.00% | New | 205 | $7K |
| Allworth Financial LP | 0.00% | New | 100 | $4K |
| JPMorgan Chase & Co. | 0.00% | Reduce -95.1% | 100 | $4K |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 16 | $583 |
| Barclays PLC | 0.00% | New | 12 | $437 |
"% of holder's portfolio" is MNPR's weight in each manager's 13F, not the share of Monopar Therapeutics Inc. the manager owns.